U-Blot® Research Grade Codrituzumab

Name: U-Blot® Research Grade Codrituzumab
SKU: WA2621
Availability: InStock

$9,999.00

Size:50ug

SKU: WA2621-50

Catalog No.: WA2621

Specification: 50ug/100ug

Stock: In stock

Product details, specifications, documents, and related products are available from the catalog record. Learn more

Product details Specifications Q & A Education

Product details, specifications, documents, and related products are available from the catalog record.

Product Overview

Catalog No.: WA2621
SKU: WA2621-50
Category: Biosimilar Antibodies
Product Type: Other
Size: 50ug/100ug
Stock Status: In stock
Available Stock: 999
Minimum Order Quantity: 1

Storage & Compliance

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Research Use Only: Yes

Additional Specifications

PackSize: 50ug/100ug
Target: GPC3
Reactivity: Human
Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host Species: Humanized
Isotype: IgG1-kappa
Conjugate/Modification: --
Recommended Dilution Ratio: --
Composition: 0.01M PBS, pH 7.4.
Purification Process: Protein A/G purified from cell culture supernatant.
Purity: >95% purity as determined by SDS-PAGE.
storageCondition: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Clonality: Monoclonal
Clone Number: --
Immunogen: Mammalian Cells
Alias: GPC3, MXR7, GTR2-2, Glypican-3, Intestinal protein OCI-5, OCI5
Species: --
Gene ID-1: P51654
Uniprot: --
Background: Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. This drug is developed by Chugai Pharmaceutical in combination with Roche and has been investigated in the treatment of liver cancer. The specific expression of GPC3 is high in hepatocellular carcinoma (HCC) tissues, which suggests that GPC3 has obvious sensitivity and specificity in the diagnosis of hepatocellular carcinoma, and can be used as a new target for the treatment of hepatocellular carcinoma. Codrituzumab did not show significant inhibition of GPC3 in the phase I trial in combined with sorafenib and the phase II trial placebo-controlled study in patients with advanced liver cancer. Codrituzumab did not show significant inhibition of GPC3 in phase I trials and phase II trials combined with sorafenib in patients with advanced liver cancer. However, the effect of codrituzumab in the treatment of liver cancer is still under study. In 2018, researchers conducted trials such as the distribution of codrituzumab and the impact of overall survival in patients with hepatocellular carcinoma. In the combined analysis of tumor cell surface antigen GPC3 and NK cell surface antigen CD16 in patients with liver cancer, it was found that codrituzumab only had a certain therapeutic effect on patients with high expression level of GPC3 and CD16. These results suggest that GPC3 and CD16 can be used as a composite biomarker to select hepatocellular carcinoma patients for codrituzuma.<br>• Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5., PMID:9133586<br/>
Tissue Expression: --
Signaling_pathway: --
Research Areas: --

Tech Support

ucallm

Documents

Datasheet, COA, SDS, and protocol files can be requested from technical support.

Storage & Handling

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.